A
ELVN icon

AlphaQuest’s Enliven Therapeutics ELVN Stock Holding History

AlphaQuest’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,337
Closed -$159K – 643
2025
Q4 		$159K Buy
10,337
+5,636
+120% +$112K 0.01% 1547
2025
Q3 		$96.2K Buy
+4,701
New +$94.8K 0.01% 1743
2025
Q2 		– Sell
-776
Closed -$15.3K – 2109
2025
Q1 		$15.3K Buy
776
+54
+7% +$1.16K ﹤0.01% 1746
2024
Q4 		$16.2K Sell
722
-20,395
-97% -$529K ﹤0.01% 1439
2024
Q3 		$539K Buy
21,117
+19,525
+1,226% +$452K 0.05% 625
2024
Q2 		$37.2K Buy
1,592
+742
+87% +$15.6K 0.01% 1172
2024
Q1 		$15K Buy
+850
New +$13K ﹤0.01% 1054

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AlphaQuest's ELVN Position: Q1 2026 in Review

AlphaQuest sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 10,337 shares — an estimated $159K sold.

AlphaQuest first reported a position in ELVN in Q1 2024 and held it in 7 quarters. The position peaked at $539K in Q3 2024. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • AlphaQuest reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 10,337 Enliven Therapeutics shares in Q1 2026, an estimated $159K.
  • AlphaQuest first reported a position in Enliven Therapeutics in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's Enliven Therapeutics position peaked at $539K in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.